How to Less development patent retrieval - Eureka

Q: How to Less development?

Lamp driving topology,Triazole compounds that modulate Hsp90 activity,Triazole compounds that modulate Hsp90 activity,Triazole compounds that modulate Hsp90 activity,Triazole compounds that modulate HSP90 activity

Lamp driving topology

InactiveUS6559606B1Low voltage requirementLess developmentElectrical apparatusElectric light circuit arrangementPhase shiftedEngineering

A lamp driving system that includes a first impedance and a second impedance coupled to the secondary side of a transformer, where the second impedance has a phase shifted value compared to the first impedance. Two lamp loads are connected in series together, and in parallel to the first and second impedances and to the transformer. The phase shift between the impedances ensures that the transformer need not supply double the striking voltage to strike the series-connected lamps. A difference in the resistance between the first and second impedances ensures that the lamps ignite in a specified sequence.

View all

Owner:O2 MICRO INT LTD

Triazole compounds that modulate Hsp90 activity

ActiveUS20060167070A1Reduced growth rateInhibit tumor growthBiocideOrganic chemistryTriazole antifungalsHSP90 Heat-Shock Proteins

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Triazole compounds that modulate Hsp90 activity

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate Hsp90 activity

ActiveUS7825148B2Less developmentBiocideOrganic chemistryDiseaseHsp90

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate Hsp90 activity

ActiveUS8053456B2Less developmentAntibacterial agentsBiocideHsp90Stereochemistry

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate HSP90 activity

ActiveUS8299107B2Reduce expressionReduce productionAntibacterial agentsBiocideStereochemistryTriazole

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to the use of a substituted triazole compound of the invention, or a composition comprising such a compound in the preparation of a medicament for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof.

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate HSP90 activity

ActiveUS20080090887A1Less developmentAntibacterial agentsBiocideTriazole antifungalsHSP90 Heat-Shock Proteins

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate HSP90 activity

ActiveUS8742133B2Less developmentAntibacterial agentsOrganic active ingredientsHsp90Stereochemistry

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate HSP90 activity

ActiveUS7662813B2Less developmentBiocideOrganic chemistryHSP90 Heat-Shock ProteinsStereochemistry

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

View all

Owner:SYNTA PHARMA CORP

Compounds that modulate HSP90 activity and methods for identifying same

InactiveUS20080027047A1Less developmentBiocideCompound screeningHSP90 Heat-Shock ProteinsStereochemistry

The present invention relates to compositions and methods related to inhibitors of Hsp90, including substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. The invention further provides methods for designing and identifying inhibitors of Hsp90.

Compounds that modulate HSP90 activity and methods for identifying same

View all

Owner:SYNTA PHARMA CORP

Triazole compounds that modulate Hsp90 activity

ActiveUS20080176840A1Low oral bioavailabilityLimited solubilityAntibacterial agentsBiocideDiseaseHsp90

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

View all

Owner:SYNTA PHARMA CORP

Imidazole compounds that modulate HSP90 activity

ActiveUS20070087998A1Less developmentBiocideGroup 5/15 element organic compoundsArylPharmaceutical drug

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.

Imidazole compounds that modulate HSP90 activity

View all

Owner:SYNTA PHARMA CORP

Pyrazole compounds that modulate HSP90 activity

ActiveUS7608635B2Less developmentBiocideSenses disorderArylNitrogen

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell.Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.

Pyrazole compounds that modulate HSP90 activity

View all

Owner:SYNTA PHARMA CORP

Electrophotographic developer and carrier therefor, core material particle for carrier for electrophotographic developer and production method thereof and image forming method

ActiveUS20070243482A1Minimize toner spentImprove image qualityElectrographic process apparatusDevelopersCost effectivenessEngineering

The present invention can provide small-diameter core material particles for electrophotographic carrier, the particles that can prevent occurrences of carrier adhesions and reduce toner spent, have excellent durability and cause little fluctuations in image density with a narrow particle diameter distribution, and an efficient, cost-effective production method thereof. That is, the core material particles for electrophotographic carrier are particles wherein the weight average particle diameter, Dw, is in the range of 22 μm to 32 μm, the ratio of Dw to the number average particle diameter, Dp, satisfies the condition, 1<Dw / Dp<1.20, the content of particles smaller than 20 μm in diameter is in the range of 0% by mass to 7% by mass and smaller than 36 μm is in the range of 90% by mass to 100% by mass, and the BET specific surface area is in the range of 300 cm2 / g to 900 cm2 / g.

Electrophotographic developer and carrier therefor, core material particle for carrier for electrophotographic developer and production method thereof and image forming method

View all

Owner:RICOH KK

Methods of organ regeneration

InactiveUS20050158288A1Less developmentIncrease secretionOrganic active ingredientsSenses disorderSpleen cellHuman patient

The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.

View all

Owner:THE GENERAL HOSPITAL CORP

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

ActiveUS20130045217A1Easy diagnosisSuperior prognostic valueBiocideComponent separationLipidomeClinical marker

The present invention inter alia provides a method, and use thereof, of diagnosing and / or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and / or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and / or an antibody thereto, for use in the prediction and / or diagnosis of atherosclerosis or CVD.

Lipidomic biomarkers for atherosclerosis and cardiovascular disease

View all

Owner:ZORA BIOSCIENCES OY

Positive-working resist composition

InactiveUS6939662B2Sufficient transmissionHigh sensitivityPhotosensitive materialsRadiation applicationsActinic RaysPhotochemistry

A positive-working resist composition comprising:(A1) a resin containing a repeating unit represented by the specific formula, which increases the solubility in an alkali developing solution by the action of an acid, and(B) a compound capable of generating an acid upon irradiation with one of actinic rays and radiation.

View all

Owner:FUJIFILM CORP +1

Trizaole compounds that modulate hsp90 activity

ActiveUS20120122869A1Less developmentAntibacterial agentsBiocideStereochemistry

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Owner:SYNTA PHARMA CORP

Hydrazonamide Compounds That Modulate Hsp90 Activity

ActiveUS20120046288A1Less developmentBiocideOrganic chemistryMedicineCancer

The present invention relates to substituted hydrazonamide compounds. The invention further relates to methods of inhibiting the activity of Hsρ90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted hydrazonamide compound of the invention, or a pharmaceutical composition comprising such a compound.

Hydrazonamide Compounds That Modulate Hsp90 Activity

View all

Owner:SYNTA PHARMA CORP

Detection of improper viewing posture

ActiveUS20170068314A1Less developmentReduce effortInput/output for user-computer interactionImage analysisComputer scienceView angle

Embodiments of the present invention provide efficient and automatic systems and methods for regulating the viewing posture of a user. Embodiments of the present invention can be used to regulate the viewing posture of both juveniles and adults, by providing real-time data analysis of a viewing distance and viewing angle of a device, and generating feedback to a user related to their current viewing posture, while also providing increased supervision of the viewing posture of juvenile device users.

View all

Owner:IBM CORP

Error correction coding method for a high-density storage media

InactiveUS7080293B2Less hardware development costLess production costError detection/correctionCode conversionComputer hardwareError correction coding

The present invention relates to an error correction encoding method for a high-density storage medium. This method arranges sequential input data so as to form a plurality of data blocks of a predefined matrix form, the plurality of data blocks being made sequentially, appends outer parity to each column of each data block in the column direction, appends inner parity to each row of each of the outer-parity-encoded data block in the row direction, reorders rows including outer parity so as to insert them separately into the other rows including no outer parity for each of the outer- and inner-parity-encoded data blocks, and writes rows in the same order in the reordered data blocks to a storage medium sequentially on row-by-row basis.

Error correction coding method for a high-density storage media

View all

Owner:LG ELECTRONICS INC

Water purifying and sterilizing disinfectant

InactiveCN101785480AGood removal effectGood killing performanceBiocideDisinfectantsEcological environmentMass ratio

The invention discloses a water purifying and sterilizing disinfectant, which comprises the following components: a potassium monopersulfate triple salt, a peroxide activation catalyst and an active halide preparation, wherein the mass ratio of the potassium monopersulfate triple salt to the peroxide activation catalyst is 500:1 to 5,000:1; and the mass ratio of the potassium monopersulfate triple salt to the active halide preparation is 1:1 to 10:1. The disinfectant has high water toxic matter removal capacity and high microorganism killing performance, avoids damaging human beings, animals and ecological environment, overcomes the drawbacks of relatively low oxidability, large using amount and generation of a large amount of by-products of chlorine, the drawbacks caused by the extremely short acting period and relatively high oxidability of ozone, has an extremely high sterilizing capacity that helps to reduce the using amount and acting period. And the disinfectant is free from residue and odor and is high in stability and extremely low in use cost.

Owner:CHENGDU ROSUN DISINFECTION PHARMA

Dynamic web based jar file finder

ActiveUS7263696B1Easy to modifyGood flexibilityProgram loading/initiatingMemory systemsHard codingSoftware development

A technique for enhancing the startup operation of a user application within a client server network. At least the client is running software in JAVA language. Java Archive (JAR) files needed for startup are housed in the server. Rather than hard code the Jar files which makes upgrades difficult, embodiments of the present invention employ two applets operating on the same HTML page in the client. One applet, the Jar finder applet obtains all Jar files needed for startup from lists of Jar files stored in a directory which is also housed in the server. This directory is readily accessible to software developers allowing its easy modification by adding or removing Jar files or by substituting an entirely new directory. Another applet, the Jar user applet (or user application) receives the lists of Jar files from the Jar finder applet and thereafter obtains the actual Jar files from the directory in the server. After loading the Jar files, the Jar user applet launches the user application and the startup operation of the network is concluded.

View all

Owner:EMC IP HLDG CO LLC

Triazinone and diazinone derivatives useful as HSP90 inhibitors

ActiveUS8524712B2Less developmentAntibacterial agentsBiocideMedicineHsp Inhibitor

The present invention relates to compounds according to formulae (IA) to (ID) and compositions that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.

Triazinone and diazinone derivatives useful as HSP90 inhibitors

View all

Owner:SYNTA PHARMA CORP

Imidazole compounds that modulate HSP90 activity

ActiveUS8629285B2Less developmentBiocideGroup 5/15 element organic compoundsArylNitrogen

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cellVariable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.

View all

Owner:SYNTA PHARMA CORP

Colored liquid-filled soft capsules and method of manufacture thereof

InactiveUS20070259035A1Easily be detected and removedLess moistureDrug compositionsCapsule deliveryCosmetic appearanceBiomedical engineering

The present invention relates to a coated liquid-filled soft capsule containing a colored shell and method for making same. The shell material contains a colorant incorporated in the material in an amount sufficient to provide a visual contrast between the capsule shell and any liquid fill that escapes from the capsule shell and resides on an exterior surface of the capsule shell. This allows leaking capsules as well as other capsules that get contaminated from the leaking capsules to be identified before they are coated. This prevents coating problems in pan and / or continuous coaters associated with leaking and / or contaminated capsules. The present invention also produces pharmaceutically elegant capsules uniform in appearance without the necessity of coloring the coating.

Owner:LEINER HEALTH PRODUCTS

Method and Apparatus for Developing Medical Training Scenarios

ActiveUS20130280685A1Less developmentMedical simulationMental therapiesComputer scienceMedical treatment

A medical training development system for development of medical training scenarios (15) is disclosed. The medical training development system comprises a repository (110) with a plurality of pre-programmed event modules (120) and pre-programmed medical training scenarios (15′). A scenario programming system (140) is connectable to the repository (110) for accessing the event modules (120) and the pre-programmed medical training scenarios (15) for programming the medical training scenarios (15′).

Method and Apparatus for Developing Medical Training Scenarios

View all

Owner:LAERDAL MEDICAL AS

Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients

ActiveUS20130216560A1Easy diagnosisSuperior prognostic valueBiocideOmicsCoronary artery diseaseBiomarker (petroleum)

The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients

View all

Owner:ZORA BIOSCIENCES OY

Method and apparatus for developing medical training scenarios

ActiveUS9886873B2Less developmentMedical simulationCosmonautic condition simulationsComputer scienceMedical treatment

A medical training development system for development of medical training scenarios (15) is disclosed. The medical training development system comprises a repository (110) with a plurality of pre-programmed event modules (120) and pre-programmed medical training scenarios (15′). A scenario programming system (140) is connectable to the repository (110) for accessing the event modules (120) and the pre-programmed medical training scenarios (15) for programming the medical training scenarios (15′).

View all

Owner:LAERDAL MEDICAL AS

Actinic ray-sensitive or radiation-sensitive resin composition and method of forming pattern therewith

ActiveUS20110081612A1Reduce roughnessExcellent dry etching resistancePhotosensitive materialsSemiconductor/solid-state device manufacturingArylActinic Rays

According to one embodiment, an actinic ray-sensitive or radiation-sensitive resin composition includes (A) a resin containing the repeating units of formulae (I), (II) and (III) that when acted on by an acid, becomes soluble in an alkali developer, and (B) a compound that when irradiated with actinic rays or radiation, generates a fluorine-containing acid,wherein each of R1 independently represents a hydrogen atom or an optionally substituted methyl group, R2 represents a halogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group or an optionally substituted aralkyl group, and n is an integer of 0 to 5, provided that when n is 2 or greater, multiple R2s may be identical to or different from each other.